Mayinglong Pharmaceutical Group Co., Ltd. (600993) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Mayinglong Pharmaceutical Group Co., Ltd.

Why is Mayinglong Pharmaceutical Group Co., Ltd. ?

Poor long term growth as Net Sales has grown by an annual rate of 8.44% and Operating profit at 10.29% over the last 5 years

Flat results in Sep 25

INTEREST(HY) At CNY 3.92 MM has Grown at 29.66%
DEBT-EQUITY RATIO (HY) Highest at -55.84 %

With ROE of 13.73%, it has a attractive valuation with a 2.75 Price to Book Value

Over the past year, while the stock has generated a return of 10.51%, its profits have risen by 15.7% ; the PEG ratio of the company is 1.3
At the current price, the company has a high dividend yield of 2.3

Underperformed the market in the last 1 year

The stock has generated a return of 10.51% in the last 1 year, much lower than market (China Shanghai Composite) returns of 22.49%

Real-Time Research Report

Verdict Report

How much should you hold?

Overall Portfolio exposure to Mayinglong Pharmaceutical Group Co., Ltd. should be less than 10%
Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Mayinglong Pharmaceutical Group Co., Ltd. for you?

Low Risk, Low Return

Absolute

Risk Adjusted

Volatility

Mayinglong Pharmaceutical Group Co., Ltd.

-17.23%

-0.36

23.07%

China Shanghai Composite

23.91%

1.58

14.20%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

3.39%

EBIT Growth (5y)

11.30%

EBIT to Interest (avg)

47.69

Debt to EBITDA (avg)

Net Debt to Equity (avg)

-0.61

Sales to Capital Employed (avg)

0.82

Tax Ratio

16.31%

Dividend Payout Ratio

51.89%

Pledged Shares

Institutional Holding

ROCE (avg)

36.83%

ROE (avg)

13.86%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

2.19

EV to EBIT

11.72

EV to EBITDA

10.53

EV to Capital Employed

3.53

EV to Sales

1.96

PEG Ratio

1.43

Dividend Yield

2.65%

ROCE (Latest)

30.13%

ROE (Latest)

13.52%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bearish

RSI

No Signal

Bollinger Bands

Mildly Bearish

Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Mildly Bearish

Dow Theory

Mildly Bearish

OBV

No Trend

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

7What is working for the Company

INTEREST COVERAGE RATIO(Q)

Highest at 21,676.56

RAW MATERIAL COST(Y)

Fallen by -0.11% (YoY

INVENTORY TURNOVER RATIO(HY)

Highest at 7.55 times

PRE-TAX PROFIT(Q)

Highest at CNY 250.83 MM

NET PROFIT(Q)

Highest at CNY 208.86 MM

EPS(Q)

Highest at CNY 0.49

-5What is not working for the Company

INTEREST(9M)

At CNY 5.01 MM has Grown at 8.28%

DEBT-EQUITY RATIO (HY)

Highest at -51.3 %

DEBTORS TURNOVER RATIO(HY)

Lowest at 5.04 times

Here's what is working for Mayinglong Pharmaceutical Group Co., Ltd.

Interest Coverage Ratio

Highest at 21,676.56

in the last five periods

MOJO Watch

The company's ability to manage interest payments is improving

Operating Profit to Interest

Pre-Tax Profit

Highest at CNY 250.83 MM

in the last five periods

MOJO Watch

Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (CNY MM)

Net Profit

Highest at CNY 208.86 MM

in the last five periods

MOJO Watch

Near term Net Profit trend is positive

Net Profit (CNY MM)

EPS

Highest at CNY 0.49

in the last five periods

MOJO Watch

Increasing profitability; company has created higher earnings for shareholders

EPS (CNY)

Inventory Turnover Ratio

Highest at 7.55 times

in the last five Semi-Annual periods

MOJO Watch

Company has been able to sell its inventory faster

Inventory Turnover Ratio

Raw Material Cost

Fallen by -0.11% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Mayinglong Pharmaceutical Group Co., Ltd.

Debt-Equity Ratio

Highest at -51.3 % and Grown

In each half year in the last five Semi-Annual periods

MOJO Watch

The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio

Interest

At CNY 5.01 MM has Grown at 8.28%

over previous Semi-Annual period

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (CNY MM)

Debtors Turnover Ratio

Lowest at 5.04 times

in the last five Semi-Annual periods

MOJO Watch

Company's pace of selling Debtors has slowed

Debtors Turnover Ratio